In this application note we present the utility of RapiFluor-MS coupled with UPLC-FLR-MS for monitoring labeled glycans ranging across a range of properties, masses, and relative abundance.
Glycosylation of is a complex and critical aspect of most therapeutic proteins which must be well characterized. Often, the profile of N-glycans is identified as a critical quality attribute and as a result is monitored throughout the lifecycle of products. As discussed in this application note, preparation of samples with a GlycoWorks RapiFluor-MS N-Glycan Kit can dramatically reduce sample preparation time and complexity.
In addition, the use of RapiFluor-MS yields improved FLR sensitivity and dramatically improved MS sensitivity. Through improving glycan MS sensitivity RapiFluor-MS labeling permits the use of mass detection with the ACQUITY QDa and thereby affords greater confidence in peak monitoring across the range of structures encountered during biopharmaceutical development.
Used together, RapiFluor-MS labeling and HILIC-FLR-MS with ACQUITY UPLC H-Class Bio System and the ACQUITY QDa Mass Detector offer an unparalleled solution for monitoring the N-glycan profiles of biotherapeutics.